Northern California Retina Vitreous Associates /ID# 282994 — Mountain View, California

Northern California Retina Vitreous Associates /ID# 282994 is a clinical research site located in Mountain View, California, United States 94040-4119.

Crixeo Clinical Trials Trust Score: 9/100 (FAILING). This profile has not yet been claimed by the site owner.

Northern California Retina Vitreous Associates /ID# 282994 has participated in 1 clinical trials with 1 currently active.

Therapeutic areas: Diabetic Retinopathy.

Sponsors: AbbVie.

Is this your site?

Is this your site? Claim your profile and control the information sponsors and patients see.

Other research sites in Mountain View

Browse all research sites in California · View every site in Mountain View

Sponsor Feasibility Report

Trust Score: 9/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Northern California Retina Vitreous Associates /ID# 282994?

Northern California Retina Vitreous Associates /ID# 282994 has a Crixeo Trust Score of 9/100 (FAILING). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Northern California Retina Vitreous Associates /ID# 282994 conducted?

Northern California Retina Vitreous Associates /ID# 282994 has 1 clinical trials on record, with 1 currently active. Their work covers Diabetic Retinopathy.

Is Northern California Retina Vitreous Associates /ID# 282994 accredited by Crixeo Clinical Trials?

Northern California Retina Vitreous Associates /ID# 282994 has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about Northern California Retina Vitreous Associates /ID# 282994?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.